Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice
Journal of Cutaneous Immunology and Allergy · 2022-04 · 5 (2) · 69-71
DOI: 10.1002/cia2.12212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cutaneous Immunology and Allergy, online erschienen am 27.09.2021. Verfasst von Marin Kunimoto und 7 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Kunimoto, M., Imai, Y., Matsutani, M., Nakatani‐Kusakabe, M., Nagai, M., Natsuaki, M., Yamanishi, K., & Kanazawa, N. (2022). Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice. Journal of Cutaneous Immunology and Allergy, 5(2), 69-71. https://doi.org/10.1002/cia2.12212
Vancouver
Kunimoto M, Imai Y, Matsutani M, Nakatani‐Kusakabe M, Nagai M, Natsuaki M, et al. Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice. Journal of Cutaneous Immunology and Allergy. 2022;5(2):69-71. doi:10.1002/cia2.12212
BibTeX
@article{Kunimoto2022,
author = {Kunimoto, Marin and Imai, Yasutomo and Matsutani, Masako and Nakatani‐Kusakabe, Minori and Nagai, Makoto and Natsuaki, Masaru and Yamanishi, Kiyofumi and Kanazawa, Nobuo},
title = {Evaluation of long‐term disease control with dupilumab therapy using the Atopic Dermatitis Control Tool in real‐world clinical practice},
journal = {Journal of Cutaneous Immunology and Allergy},
year = {2022},
volume = {5},
number = {2},
pages = {69--71},
doi = {10.1002/cia2.12212}
}
EUVIMED